Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The documentation on indolent B-cell non-Hodgkin lymphoma is limited due to its relatively rare occurrence and the variability in clinical presentation among patients. As this condition affects fewer individuals, systematic clinical studies have been challenging to conduct, which has resulted in gaps in our understanding. Ongoing research may help to clarify these aspects in the future.
To navigate your care for indolent B-cell non-Hodgkin lymphoma, consider seeking a hematologist or oncologist with expertise in lymphoma treatment. They can provide tailored advice and treatment options. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers valuable information and support. Participating in clinical trials may also be an option; visit ClinicalTrials.gov to find studies relevant to your condition.
There are currently four orphan drugs associated with indolent B-cell non-Hodgkin lymphoma, including FDA-approved treatments such as ibritumomab tiuxetan, rituximab, and tositumomab with iodine I 131. Additionally, two drugs are designated for development: Murine MAb (Lym-1) and iodine 131-I radiolabeled murine MAb (Lym-1) for human B-cell lymphoma. With 62 active clinical trials available, patients may explore potential participation opportunities by visiting ClinicalTrials.gov for more information.
Actionable guidance for navigating care for indolent B-cell non-Hodgkin lymphoma
To navigate your care for indolent B-cell non-Hodgkin lymphoma, consider seeking a hematologist or oncologist with expertise in lymphoma treatment. They can provide tailored advice and treatment options. Additionally, you can explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov, which offers valuable information and support. Participating in clinical trials may also be an option; visit ClinicalTrials.gov to find studies relevant to your condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 3 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.